Switzerland-based biopharmaceutical company Prexton Therapeutics completed a €29m ($31m) series B round featuring Merck Ventures, the corporate venturing subsidiary of pharmaceutical company Merck Group, yesterday.
The round was co-led by Forbion Capital Partners and Seroba Life Sciences and also featured fellow venture capital firms Ysios Capital and Sunstone Capital.
Prexton is developing compounds originated by Merck affiliate Merck Serono to treat central nervous system (CNS) conditions. It will use the capital to fund phase 2 studies of its lead product,…
